CFO Timothy Lorber resigns; Interim CEO Christopher Cooper assumes CFO role

Shuttle Pharmaceuticals Holdings, Inc.

Timothy Lorber resigns as CFO effective Nov 21, 2025; will provide part-time transition through Dec 4, 2025.
Christopher Cooper (Interim CEO) appointed CFO effective Nov 21, 2025 while company searches for permanent CFO.
Lorber receives $20K retention bonus on Nov 21 and $10K on Dec 4; 39,854 unvested RSUs to vest on Feb 8, 2026.
RSU vesting includes 24,854 from Aug 8, 2025 grant, 14,620 from Aug 12, 2025 grant, and 380 from June 14, 2024 grant.
Separation Agreement includes mutual release, confidentiality, and non-disparagement provisions.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.